Jon Hepple
Advisor, Life Sciences
Jon joined Oxford Science Enterprises in July 2020 and advises the Life Sciences team, bringing more than 20 years of investment experience across the life sciences industry.
He is also a Partner at Rosetta Capital, a venture capital firm focused on life sciences and medical technologies, which he co-founded in 2009.
Jon began his investment career at Rothschild Asset Management before co-founding BioScience Managers in 2001. He later served as a Partner at Seroba Life Sciences and has held numerous board director roles, including Aprea Therapeutics, Covagen, Opsona Therapeutics, Catalyst Biosciences, Glycomimetics, NovImmune, Carrick Therapeutics and Mission Therapeutics.
Jon holds a PhD in Cancer Research from the University of Cambridge and a BA in Biology from the University of Oxford.
WORK WITH US
Oxford researchers & innovators
Want your research to have real-world impact?
We partner with researchers and innovators across Oxford, Harwell and Culham to explore commercial potential, co-create ventures and build companies.
Investors
Interested in becoming an OSE shareholder?
We’ve raised over £850m from global investors keen to access Oxford’s diverse, world-leading science. Our shareholders don’t just back OSE – many also co-invest alongside us.
Co-investors
Looking to invest in Oxford’s most exciting spinouts?
We partner with specialist global investors to fund and scale our companies – from pre-seed to growth. Together, OSE and our co-investors have invested more than £3bn.